Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Bladder Cancer

  Free Subscription


24.04.2017

1 Actas Urol Esp
1 Adv Anat Pathol
1 Ann Diagn Pathol
1 Anticancer Drugs
1 Bull Cancer
1 Cancer Chemother Pharmacol
2 Clin Genitourin Cancer
1 Dis Markers
1 Drug Deliv
1 Eur Urol
1 Indian J Cancer
4 Int J Surg Pathol
1 Intern Med
1 J Pediatr Urol
2 Kaohsiung J Med Sci
1 Mol Med Rep
1 Molecules
10 Oncotarget
1 Pathology
1 Prog Urol
1 Scand J Urol
1 Turk J Med Sci
2 Urol J
1 Urol Oncol
1 Vet Comp Oncol
1 Virchows Arch
2 World J Surg Oncol
6 World J Urol
1 Zhonghua Yi Xue Za Zhi


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Actas Urol Esp

  1. MATEU L, Garcia-Cruz E, Asiain I, Castaneda R, et al
    A higher Charlson comorbidity index is related to more aggressive characteristics in de novo vesical tumours.
    Actas Urol Esp. 2016;40:23-8.
    PubMed     Text format     Abstract available


    Adv Anat Pathol

  2. SURYAVANSHI M, Sanz-Ortega J, Sirohi D, Divatia MK, et al
    S100P as a Marker for Urothelial Histogenesis: A Critical Review and Comparison With Novel and Traditional Urothelial Immunohistochemical Markers.
    Adv Anat Pathol. 2017;24:151-160.
    PubMed     Text format     Abstract available


    Ann Diagn Pathol

  3. KURTIS B, Zhuge J, Ojaimi C, Ye F, et al
    Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications.
    Ann Diagn Pathol. 2016;21:7-11.
    PubMed     Text format     Abstract available


    Anticancer Drugs

  4. HUANG XL, Zhang H, Yang XY, Dong XY, et al
    Activation of a c-Jun N-terminal kinase-mediated autophagy pathway attenuates the anticancer activity of gemcitabine in human bladder cancer cells.
    Anticancer Drugs. 2017 Apr 20. doi: 10.1097/CAD.0000000000000499.
    PubMed     Text format     Abstract available


    Bull Cancer

  5. BIGOT F, Bonnet C, Massard C
    [Immunotherapy for the treatment of patients with genitourinary cancers: Review and perspectives].
    Bull Cancer. 2017;104:370-379.
    PubMed     Text format     Abstract available


    Cancer Chemother Pharmacol

  6. SUN F, Zhao R, Zhu Y, Cui D, et al
    A prospective comparison of intra-arterial chemotherapy combined with intravesical chemotherapy and intravesical chemotherapy alone after transurethral resection with a thulium laser in high-risk non-muscle invasive bladder cancer.
    Cancer Chemother Pharmacol. 2017 Apr 18. doi: 10.1007/s00280-017-3305.
    PubMed     Text format     Abstract available


    Clin Genitourin Cancer

  7. LEONE AR, Zargar-Shoshtari K, Diorio GJ, Sharma P, et al
    Neoadjuvant Chemotherapy in Elderly Patients With Bladder Cancer: Oncologic Outcomes From a Single Institution Experience.
    Clin Genitourin Cancer. 2017 Feb 1. pii: S1558-7673(17)30030.
    PubMed     Text format     Abstract available

  8. D'ANDREA D, Moschini M, Gust K, Abufaraj M, et al
    Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Primary Non-muscle-invasive Bladder Cancer.
    Clin Genitourin Cancer. 2017 Mar 27. pii: S1558-7673(17)30069.
    PubMed     Text format     Abstract available


    Dis Markers

  9. ELHAWARY NA, Nassir A, Saada H, Dannoun A, et al
    Combined Genetic Biomarkers Confer Susceptibility to Risk of Urothelial Bladder Carcinoma in a Saudi Population.
    Dis Markers. 2017;2017:1474560.
    PubMed     Text format     Abstract available


    Drug Deliv

  10. WEI Y, Gao L, Wang L, Shi L, et al
    Polydopamine and peptide decorated doxorubicin-loaded mesoporous silica nanoparticles as a targeted drug delivery system for bladder cancer therapy.
    Drug Deliv. 2017;24:681-691.
    PubMed     Text format     Abstract available


    Eur Urol

  11. BLACK PC
    Seeking the Molecular Truth in Bladder Cancer: Biology=Genomex(Transcriptome)2.
    Eur Urol. 2017 Apr 17. pii: S0302-2838(17)30286.
    PubMed     Text format    


    Indian J Cancer

  12. LODH B, Sinam RS, Singh KA
    Adenocarcinoma of urinary bladder in patient with primary gastric cancer: An unusual synchronous distant metastasis.
    Indian J Cancer. 2016;53:53-5.
    PubMed     Text format    


    Int J Surg Pathol

  13. MITRA S, Sundaram AK, Gupta K, Devana SK, et al
    Urothelial Carcinoma With Villoglandular Differentiation: A Rare Entity.
    Int J Surg Pathol. 2016;24:356-9.
    PubMed     Text format     Abstract available

  14. MAI KT, Bateman J, Djordjevic B, Flood TA, et al
    Clear Cell Urothelial Carcinoma.
    Int J Surg Pathol. 2017;25:18-25.
    PubMed     Text format     Abstract available

  15. RAIS-BAHRAMI S, Tracht JP, McIntosh ER, Lai WS, et al
    Complete Tissue Submission to Increase Lymph Node Detection in Pelvic Lymph Node Packets Submitted for Patients Undergoing Radical Prostatectomy and Radical Cystectomy.
    Int J Surg Pathol. 2017;25:12-17.
    PubMed     Text format     Abstract available

  16. GOTO K
    CD138 Expression Is Observed in the Urothelial Epithelium and in Various Urothelial Carcinomas, and Cannot Be Evidence for Plasmacytoid Urothelial Carcinoma.
    Int J Surg Pathol. 2016;24:614-9.
    PubMed     Text format     Abstract available


    Intern Med

  17. FUKUSHIMA K, Hirosako S, Tenjin Y, Mukasa Y, et al
    Pulmonary Mucosa-associated Lymphoid Tissue Lymphoma with Spontaneous Regression after Computed Tomography-guided Needle Biopsy: A Case Report and Summary of 8 Reported Cases.
    Intern Med. 2016;55:3655-3660.
    PubMed     Text format     Abstract available


    J Pediatr Urol

  18. ANGELINI L, Bisogno G, Alaggio R, Scarzello G, et al
    Prognostic factors in children undergoing salvage surgery for bladder/prostate rhabdomyosarcoma.
    J Pediatr Urol. 2016;12:265.
    PubMed     Text format     Abstract available


    Kaohsiung J Med Sci

  19. SHAO IH, Chang YH, Yu KJ, Lin PH, et al
    Outcomes and prognostic factors of simple partial cystectomy for localized bladder urothelial cell carcinoma.
    Kaohsiung J Med Sci. 2016;32:191-5.
    PubMed     Text format     Abstract available

  20. DOGANTEKIN E, Girgin C, Gorgel SN, Soylemez H, et al
    Can immediate second resection be an alternative to standardized second transurethral resection of bladder tumors?
    Kaohsiung J Med Sci. 2016;32:147-51.
    PubMed     Text format     Abstract available


    Mol Med Rep

  21. WANG H, Yuan G, Zhao B, Zhao Y, et al
    High expression of B23 is associated with tumorigenesis and poor prognosis in bladder urothelial carcinoma.
    Mol Med Rep. 2017;15:743-749.
    PubMed     Text format     Abstract available


    Molecules

  22. LIU CW, Wu YT, Lin KJ, Yu TJ, et al
    A Hydrogel-Based Epirubicin Delivery System for Intravesical Chemotherapy.
    Molecules. 2016;21.
    PubMed     Text format     Abstract available


    Oncotarget

  23. BACCHETTI T, Sartini D, Pozzi V, Cacciamani T, et al
    Exploring the role of paraoxonase-2 in bladder cancer: analyses performed on tissue samples, urines and cell cultures.
    Oncotarget. 2017 Feb 24. doi: 10.18632/oncotarget.15674.
    PubMed     Text format     Abstract available

  24. LEONE A, Diorio G, Sexton W, Schell M, et al
    Sulforaphane for the chemoprevention of bladder cancer: molecular mechanism targeted approach.
    Oncotarget. 2017 Mar 8. doi: 10.18632/oncotarget.16015.
    PubMed     Text format     Abstract available

  25. POYET C, Thomas L, Benoit TM, Delmo DA, et al
    Implication of vascular endothelial growth factor A and C in revealing diagnostic lymphangiogenic markers in node-positive bladder cancer.
    Oncotarget. 2017;8:21871-21883.
    PubMed     Text format     Abstract available

  26. CHEN L, Pan XW, Huang H, Gao Y, et al
    Epithelial-mesenchymal transition induced by GRO-alpha-CXCR2 promotes bladder cancer recurrence after intravesical chemotherapy.
    Oncotarget. 2017 Apr 3. doi: 10.18632/oncotarget.16786.
    PubMed     Text format     Abstract available

  27. SHAO CH, Chen CL, Lin JY, Chen CJ, et al
    Metabolite marker discovery for the detection of bladder cancer by comparative metabolomics.
    Oncotarget. 2017 Mar 21. doi: 10.18632/oncotarget.16393.
    PubMed     Text format     Abstract available

  28. LIU X, Liu X, Wu Y, Wu Q, et al
    MicroRNAs in biofluids are novel tools for bladder cancer screening.
    Oncotarget. 2017 Mar 8. doi: 10.18632/oncotarget.16026.
    PubMed     Text format     Abstract available

  29. YANG G, Shen W, Zhang Y, Liu M, et al
    Accumulation of myeloid-derived suppressor cells (MDSCs) induced by low levels of IL-6 correlates with poor prognosis in bladder cancer.
    Oncotarget. 2017 Mar 20. doi: 10.18632/oncotarget.16386.
    PubMed     Text format     Abstract available

  30. CUI X, Jing X, Long C, Yi Q, et al
    Accuracy of the urine UCA1 for diagnosis of bladder cancer: a meta-analysis.
    Oncotarget. 2017 Mar 22. doi: 10.18632/oncotarget.16473.
    PubMed     Text format     Abstract available

  31. CHEN C, Hu L, Chen Y, Hou J, et al
    The prognostic value of histological subtype in patients with metastatic bladder cancer.
    Oncotarget. 2017 Mar 10. doi: 10.18632/oncotarget.16083.
    PubMed     Text format     Abstract available

  32. DUDEK AM, Boer SJ, Boon N, Witjes JA, et al
    Identification of long non-coding RNAs that stimulate cell survival in bladder cancer.
    Oncotarget. 2017 Mar 16. doi: 10.18632/oncotarget.16284.
    PubMed     Text format     Abstract available


    Pathology

  33. AMAYA CN, Wians FH Jr, Bryan BA, Torabi A, et al
    Enhanced expression of Programmed cell death 1 (PD-1) protein in benign vascular anomalies.
    Pathology. 2017;49:292-296.
    PubMed     Text format     Abstract available


    Prog Urol

  34. ALIMI Q, Peyronnet B, Kammerer-Jacquet SF, Lefevre M, et al
    [Oncologic and perioperative outcomes of robot-assisted radical cystectomy: A single-center prospective series].
    Prog Urol. 2016;26:538-46.
    PubMed     Text format     Abstract available


    Scand J Urol

  35. STYRKE J, Henriksson H, Ljungberg B, Hasan M, et al
    Evaluation of the diagnostic accuracy of UBC(R) Rapid in bladder cancer: a Swedish multicentre study.
    Scand J Urol. 2017 Apr 19:1-8. doi: 10.1080/21681805.2017.1313309.
    PubMed     Text format     Abstract available


    Turk J Med Sci

  36. OZGOZ A, Samli M, Dincel D, Sahin A, et al
    Association of B7-H4 gene polymorphisms in urothelial bladder cancer.
    Turk J Med Sci. 2017;47:443-446.
    PubMed     Text format     Abstract available


    Urol J

  37. SEVINC C, Ozkaptan O, Balaban M, Yucetas U, et al
    Radical Cystoprostatectomy in Patients with Behcet's Disease: The Report of Four Cases and Review of The Literature.
    Urol J. 2016;13:2871-2875.
    PubMed     Text format    

  38. YIKILMAZ TN, Dirim A, Ayva ES, Ozdemir H, et al
    Clinical Use of Tumor Markers for the Detection and Prognosis of Bladder Carcinoma: A Comparison of CD44, Cytokeratin 20 and Survivin.
    Urol J. 2016;13:2677-83.
    PubMed     Text format     Abstract available


    Urol Oncol

  39. HAU AM, Nakasaki M, Nakashima K, Krish G, et al
    Differential mTOR pathway profiles in bladder cancer cell line subtypes to predict sensitivity to mTOR inhibition.
    Urol Oncol. 2017 Apr 18. pii: S1078-1439(17)30134.
    PubMed     Text format     Abstract available


    Vet Comp Oncol

  40. HANAZONO K, Nishimori T, Fukumoto S, Kawamura Y, et al
    Immunohistochemical expression of p63, Ki67 and beta-catenin in canine transitional cell carcinoma and polypoid cystitis of the urinary bladder.
    Vet Comp Oncol. 2016;14:263-9.
    PubMed     Text format     Abstract available


    Virchows Arch

  41. EICH ML, Dyrskjot L, Netto GJ
    Toward personalized management in bladder cancer: the promise of novel molecular taxonomy.
    Virchows Arch. 2017 Apr 21. doi: 10.1007/s00428-017-2119.
    PubMed     Text format     Abstract available


    World J Surg Oncol

  42. CHO MH, Kim SH, Park WS, Joung JY, et al
    Bladder chondrosarcoma plus urothelial carcinoma in recurred transitional cell carcinoma of the upper urinary tract: a case report and literature review.
    World J Surg Oncol. 2016;14:270.
    PubMed     Text format     Abstract available

  43. PASCHKE L, Juszczak M, Slupski M
    Surgical treatment of recurrent urachal carcinoma with liver metastasis: a case report and literature review.
    World J Surg Oncol. 2016;14:296.
    PubMed     Text format     Abstract available


    World J Urol

  44. VILLA L, Cloutier J, Letendre J, Ploumidis A, et al
    Early repeated ureteroscopy within 6-8 weeks after a primary endoscopic treatment in patients with upper tract urothelial cell carcinoma: preliminary findings.
    World J Urol. 2016;34:1201-6.
    PubMed     Text format     Abstract available

  45. GRIMM T, Buchner A, Schneevoigt B, Kretschmer A, et al
    Impact of preoperative hemoglobin and CRP levels on cancer-specific survival in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: results of a single-center study.
    World J Urol. 2016;34:703-8.
    PubMed     Text format     Abstract available

  46. ZARGAR-SHOSHTARI K, Zargar H, Dinney CP, Ercole CE, et al
    Clinical and therapeutic factors associated with adverse pathological outcomes in clinically node-negative patients treated with neoadjuvant cisplatin-based chemotherapy and radical cystectomy.
    World J Urol. 2016;34:695-701.
    PubMed     Text format     Abstract available

  47. MAY M, Fritsche HM, Vetterlein MW, Bastian PJ, et al
    Impact of photodynamic diagnosis-assisted transurethral resection of bladder tumors on the prognostic outcome after radical cystectomy: results from PROMETRICS 2011.
    World J Urol. 2017;35:245-250.
    PubMed     Text format     Abstract available

  48. GOLABEK T, Palou J, Rodriguez O, Gaya JM, et al
    Is it possible to stop follow-up of patients with primary T1G3 urothelial carcinoma of the bladder managed with intravesical bacille Calmette-Guerin immunotherapy?
    World J Urol. 2017;35:237-243.
    PubMed     Text format     Abstract available

  49. BREYER J, Gierth M, Shalekenov S, Aziz A, et al
    Epithelial-mesenchymal transformation markers E-cadherin and survivin predict progression of stage pTa urothelial bladder carcinoma.
    World J Urol. 2016;34:709-16.
    PubMed     Text format     Abstract available


    Zhonghua Yi Xue Za Zhi

  50. YANG LL, Wang XY, Zheng LY, Fang SJ, et al
    [The role of FOXO3a-Bim signaling in triptolide induced bladder cancer T24 cells apoptosis].
    Zhonghua Yi Xue Za Zhi. 2017;97:1187-1190.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: